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metastatic PC3 and DU145 cells). Co-culture fibroblasts with
LNCaP cells resulted in significant down-regulation of expression
of glypican-1 and up-regulation of CSPG4/NG2 expression in the
fibroblasts, changing overall proteoglycans expression pattern in
the cells. Interestingly, CSPG4/NG2 expression is more character-
istic for nerve cells and cancer stem cells, and up-regulation of
the gene in the cancer cell-exposed fibroblasts may argue for their
dedifferentiation. Co-culture fibroblasts with more aggressive
DU145 and PC3 resulted in similar results with an additional
down-regulation of versican expression. This data show, that
prostate cancer cells affect normal fibroblasts by the other way
than normal prostate cells and stimulate them to express another
set of proteoglycans, which usually are expressed in poor-
differentiated or morphologically different cells. Data obtained
by immunocytochemical analysis confirmed RT-PCR data and
showed specific activation of some proteoglycans at the region
of contact between fibroblasts and normal but not cancer prostate
cells in co-culture. Taken together, obtained results show that
normal prostate epithelial cells affect surrounding fibroblasts
and modify transcriptional activities of proteoglycan-coding
genes in the cells, while cancer cells change the proteoglycans
expression in cancer cells-exposed fibroblasts seems contributing
to reprogramming of normal fibroblasts to CAFs. Understanding
the mechanisms of this reprogramming may help to develop a
new approach for cancer therapy based on the return reprogram-
ming of CAFs to normal fibroblasts and correction of tumour
microenvironment.
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Ability of Streptococcus pyogenes to fight cancer was discovered
and clinically tested more than 100 years ago (Coley, 1897), but the
mechanisms of these effects are unknown. Recently several
murine models demonstrating the anti-cancer activity of Group
A Streptococcus (GAS) M49 were established (Maletzki, 2008).
The present study is devoted to investigation of anti-cancer
activity of GAS M39 strains.
Materials and Methods: Tumor cells were injected subcuta-
neously in concentration of 200,000 cells per animal. Two solid
tumor models were used: hepatoma 22a in C3HA mice and
sarcoma 37 in Swiss mice. GAS (wild and mutant strains) were
injected into the tumor 2  104 per animal twice with a
5-day-interval. The influence of GAS on tumor growth was
evaluated by measurement of tumor diameter and animal
survival. Inactivation of M protein (emm) gene was generated by
insertional mutagenesis after cloning the fragment of the emm
gene in suicidal plasmid pT7ermB.The plasmid was introduced
into GAS by electroporation. Insertion had been proved by DNA
sequencing.
Results: Intratumoral injections of wild GAS M39 strain did not
influence on tumor size in mice bearing hepatoma 22a and sar-
coma 37. The second injection of GAS enhanced inhibition of
the tumor growth, but increased the death rates. The treatment
by emm mutant strain caused the inhibition of tumor growth
and showed less mortality rate both tumor models. The average
number of completely cured animals was 10%.
Conclusion: Inactivation of emm gene in GAS M39 strain
resulted in increased anti-tumor activity and decreased lethality
rate. We hypothesized that the absence of anti-phagocytic M
protein may increase phagocytosis of GAS by macrophages and
thus enhance their antitumor activity.
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Background: Microvesicles release by neoplastic cells were
found in blood and carrying a large number of tumor distinctive
molecules, like miRNA/mRNA, proteins. Considering extensive
surface of blood cells we wonder if exosomesare circulated exclu-
sively in plasma or could be associated with surface of blood cells.
Materials and Methods: Microvesicles circulating in blood of
healthy women (HW) and breast cancer patients (BCP) were stud-
ied. Blood was fractionated into plasma and cellular fractions; in
order to release cell surface bound material, blood cells were
treated as it was described for cell-surface-bound (CSB) cirDNA
(Tamkovich, 2005).Exosomes were pelleted at 100,000 g from
0.1 lm filtered supernatants obtained by plasma and CSB eluates
centrifugation at 17,000 g, resuspended in PBS and stored in
aliquots at 80 C. Size distribution of the microparticles was
characterized by TEM (Jeol, Japan), anti CD-63, CD-24, CD-9 anti-
bodies (BD Biosciences, USA) were used as exosome markers, pro-
tein concentration was measured by NanoOrange Protein
Quantitation kit (Molecular Probes, USA), total RNA and miRNA
were isolated by mirVana kit, 28S rRNA were quantified by
RT-qPCR after reverse transcription with 6-mer random primers,
miRNA using TaqMan Small RNA Assays kit (Applied Biosystems,
USA). DNA was isolated using ‘‘DNA Isolation Kit” (BioSilicaLtd,
Russia) and measured by TaqMan multiplex real-time PCR for
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LINE1 and a-satellite repeats (Bryzgunova, 2011). Results: TEM
with immunogold labeling demonstrate presence of exosomes
in 30–100 nm membrane-wrapped particles isolated from both
plasma and CSB eluates. TEM, NanoOrange and 28S rRNA
RT-qPCR data demonstrate that CSB exosomes constitutes 2/3 of
total blood exosomes. Exosomes ranged 50–70 nm prevail in blood
of BCP, whereas 30–50 nm exosomes in blood of HW. Exosomal
DNA is less than 0.3% of cell-free blood DNA. RNA integrity and
specific quantity checked by Bioanalyzer (Agilent Technologies,
USA) do not differ in cell-free and CSB exosomes. Preliminary
data demonstrate overpresentation of cancer-specific miRNA
(miR-103, miR-191, miR-195) in exosomes bound with erythro-
cyte’s as compared with exosomes bound with leukocytes or
circulating in plasma.
Conclusion: Exosomal DNA obviously do not have any diagnos-
tic value in contrast to RNA. CSB exosomes represent valuable
source of material for small-invasive cancer diagnostics.
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Background: It was shown that circulating DNA could be used
as a valuable source of material for cancer diagnostics
(Fleischhacker, 2007), but unknown and unpredictable factors
frequently dramatically decrease concentration of tumor-
specific genetic biomarkers by influencing on generation and cir-
culation in bloodstream of extracellular DNA. Sequencing of total
circulating DNA could either provide valuable information regard-
ing such factors or determine novel targets (DNA markers) for
cancer diagnostics.
Materials and Methods: We used a Sanger’s technology (ABI
PRIZM 3110 sequenator) and BLAST analysis of circulating DNA
from plasma and cell-surface-bound fraction of healthy individu-
als and patients with breast cancer. DNA was isolated by guani-
dine thiocyanate/glass milk method (Tamkovich, 2004) followed
by Sau3A and EcoRI hydrolysis. Fragmented DNAwas ligated into
the pBlueScript II KS(-) vector. Competent XL-Blue (E. coli) cells
were transformed with the vector by electroporation and after
recovery the cells were plated on LB+Amp agar plates. The inserts
length estimate by PCR-analysis.
Results: The majority of investigated circulating DNA frag-
ments were about 100–800 bp. Sequence analysis revealed that
number of circulating DNA fragments does not depend from the
size of paternal chromosome both in normal and pathological
state, but fragments from chromosome six were found in the
female bloodstream more frequently. It was found, that in cancer
patients blood were observed frequency of occurrence of pseudo
genes and CpG islands below then in healthy female blood. BLAST
analysis demonstrates that 10% of coding DNA fragments circu-
lating in blood of the breast cancer patients is associated with
development of this pathology.
Conclusion: Sequencing of circulating DNA demonstrates a
variable concentration of different DNA sequences in comparison
with genomic DNA. Further characterization of circulating DNA
may be beneficial in diagnosis and prognosis and may also con-
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Prostate cancer is presented as the most commonly diag-
nosed cancer in men. According to statistical reports, every
6th man have the prostate cancer and out of them every 34th
man will have the castrate-resistant form of disease. The exist-
ing clinical and prognostic factors can explain cancer outcome
in small part of patients. The prediction of individual prostate
cancer prognosis and anticancer therapy effect are the main
goals of the advanced personalized therapy. The modern genetic
technologies development (GWAS, genome sequencing) will
allow to find the effective prognostic markers of prostate
cancer.
During the GWAS performance it was found loci associated
with the prostate cancer development. The analysis of on-line
base ‘‘A Catalog of Published Genome-Wide Association Studies”
(www.genome.gov), containing the full information of genome
associative investigations as well as 30 studies of prostate cancer,
revealed the associations of 159 SNPs in different ethnic groups of
patients (Caucasian, Asian and Negroid). 86 SNPs among them
located in 77 genes, 65 SNPs – had the intergenic localization.
The GWAS performance in prostate cancer Caucasian patients
have found the associations of 76 SNPs in 72 genes and 65 SNPs
in intergenic regions. SNPs in genes were located in 81.4% of cases
in introns, in 5.3% – in other locations as well as missense
changes (near 50-UTR, ncRNA). It was obtained 30 markers related
to disease of different ethnic groups of patients in GWAS. 17 SNPs
among them (rs10187424, rs6545977, rs7584330, rs10936632,
rs651164, rs12155172, rs1512268, rs4242384, rs3123078,
rs11199874, rs7127900, rs7130881, rs10875943, rs4775302,
rs5759167, rs1327301, rs5919432) had the intergenic localization,
12 SNPs (rs1465618, rs12621278, rs17181170, rs6763931,
rs17021918, rs12500426, rs7679673, rs2121875, rs2242652,
rs6465657, rs7501939, rs1859962) were located in introns and
1 SNP (rs130067) – in exon.
60 EJC SUPPLEMENTS 13 (2015) 1–75
